SureTrader
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

I'll also add that the additional ask regarding

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BlackDoggie Member Profile
 
Followed By 8
Posts 509
Boards Moderated 0
Alias Born 02/17/17
160x600 placeholder
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 1/10/2018 5:01:36 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/10/2018 4:56:01 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 1/8/2018 4:37:58 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 1/8/2018 4:36:15 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/29/2017 5:18:12 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/29/2017 5:13:14 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/21/2017 4:30:41 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/21/2017 6:06:16 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/15/2017 7:37:52 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/7/2017 4:58:05 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/7/2017 4:53:09 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/6/2017 5:25:33 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/6/2017 4:32:06 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 11/27/2017 4:37:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/27/2017 4:32:49 PM
Tender Offer Statement by Issuer (sc To-i) "Edgar (US Regulatory)" - 11/24/2017 4:28:37 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 11/16/2017 4:12:12 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/8/2017 4:34:16 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/8/2017 4:34:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/2/2017 4:33:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/13/2017 7:20:39 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/11/2017 7:53:23 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 7:46:31 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 10/10/2017 9:05:18 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/5/2017 2:56:11 PM
BlackDoggie   Friday, 11/10/17 11:37:33 AM
Re: BlackDoggie post# 18097
Post # of 19467 
I'll also add that the additional ask regarding patients for safety data may appear out of line with that reasoning at first blush. However, if I'm the FDA, and I'm agreeing to consider labeling more broadly than for a very small subset of very sick patients, I might want more safety data to justify it. Basically, if the company wants to market the drug (via the combo application) to a patient population that is less gravely ill than the patients they were originally restricted to, then the FDA might reasonably want more assurance that the drug is safe to offer to patients who may have options.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist